For the POPLAR/OAK cohort, 35 patients with previously treated metastatic NSCLC harboring BRAF mutations were identified in the POPLAR (n = 7) and OAK (n = 28) trials (Figure 2C). Here, BRAF is linked to non-small cell lung carcinoma.